Dosage unit comprising a prostaglandin analog for treating constipation
View Patent ↗A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention includes a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects. In particular, the dosage unit includes a prostaglandin (PG) analog represented by Formula (I) and/or its tautomers, and a pharmaceutically suitable excipient, wherein the dosage unit contains the PG analog in an amount of 24 μg+/−10%:
1. A dosage unit comprising a prostaglandin (PG) analog represented by Formula (I) and/or its tautomers, and a pharmaceutically suitable excipient, wherein the dosage unit contains said PG analog in an amount of 24 μg+/−10%:
where A 1 and A 2 are fluorine atoms and
B is —COOH, including its pharmaceutically acceptable salts, esters or amides.
2. The dosage unit of claim 1 , wherein said PG analog is the monocyclic tautomer of formula (I).
3. The dosage unit of claim 1 , wherein said PG analog is the bi-cyclic tautomer of formula (I).
4. The dosage unit of claim 1 , wherein said pharmaceutically suitable excipient is orally acceptable.
5. The dosage unit of claim 1 , wherein said pharmaceutically suitable excipient is a medium chain fatty acid.
6. The dosage unit of claim 1 , wherein B is —COOH.
7. The dosage unit of claim 1 , which is suitable for use in a human patient.
8. The dosage unit of claim 7 , which is suitable for use in relieving or preventing constipation.
9. The dosage unit of claim 5 , wherein B is —COOH.
10. The dosage unit of claim 1 , wherein the PG analog is present in an amount of 24 μg.
11. The dosage unit of claim 10 , wherein B is —COOH.
12. The dosage unit of claim 10 , wherein said pharmaceutically suitable excipient is a medium chain fatty acid.
13. The dosage unit of claim 11 , wherein said pharmaceutically suitable excipient is a medium chain fatty acid.